This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Philip Morris (PM) Q4 Earnings: Low Cigarette Volumes to Hurt
by Zacks Equity Research
Philip Morris' (PM) performance in Q4 to be weighed down by declining cigarette sales volumes. However, strength in RRPs and pricing to offer some respite.
Altria's (MO) Q4 Earnings to Gain From Prudent Pricing & RRPs
by Zacks Equity Research
Altria (MO) gains from higher pricing as well as rising popularity of low risk tobacco products. However, declining cigarette sales volumes is a worry.
Is British American (BTI) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if British American (BTI) stock is a good choice for value-oriented investors right now from multiple angles.
Can Altria's Expansion in RRPs & Cannabis Enable a Revival?
by Zacks Equity Research
Altria (MO) strives to expand in RRPs and Cannabis to stay afloat, amid receding cigarette sales.
Will RRPs Curate a Comeback for Philip Morris (PM) in 2019?
by Zacks Equity Research
Philip Morris (PM) witnesses receding cigarette sales volumes. Nevertheless, the company's advancement in low-risk tobacco alternatives is encouraging.
Altria (MO) Confirms Deal With JUUL, Unveils Savings Plan
by Zacks Equity Research
Altria's (MO) deal with JUUL to boost strength in reduced risk products realm. Further, the company reiterates earnings view for 2018.
Altria Likely to Invest in Juul to Bolster E-Cigarettes Unit
by Zacks Equity Research
Altria (MO) is undertaking efforts to boost smokeless offerings. Per market reports, the company is considering an investment in Juul.
Can Altria (MO) Rebound From a Terrible 2018?
by Zacks Equity Research
Stringent FDA regulations have led to fading cigarette sales that are plaguing the performance of Altria. Nevertheless, growth in RRPs looks encouraging.
Will Pricing & Smokeless Unit Aid Altria's (MO) Q3 Earnings?
by Zacks Equity Research
Altria's (MO) Q3 performance to gain from strong pricing and strength in low risk alternatives. However, declining cigarette volumes is a concern.
Philip Morris (PM) Q3 Earnings: Cigarette Woes Dim Prospects
by Zacks Equity Research
Philip Morris' (PM) Q3 performance to be hurt by lower cigarette sales volumes. Nevertheless, performance of RRPs is expected to be strong.
What FDA's Stance on E-Cigarettes Means for Tobacco Stocks
by Zacks Equity Research
The FDA announces directives to curb e-cigarette usage among youngsters. Though this caused tobacco stocks to gain recently, it is yet to be seen if the upside can be sustained.
Altria (MO) Shares Up Close to 7% on FDA's Latest Notice
by Zacks Equity Research
The FDA reveals serious enforcement actions related to the marketing and sale of e-cigarettes to minors, which may benefit tobacco players like Altria (MO).
New Strong Sell Stocks for August 30th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Altria Hikes Divident by 14.3%, Boosts Shareholders' Value
by Zacks Equity Research
Altria (MO) continues to be committed toward enhancing shareholder value. The company hikes quarterly dividend rates from 70 cents per share to 80 cents.
Altria (MO) Q2 Earnings: Can Smokeless Products Offset Woes?
by Zacks Equity Research
Altria's (MO) Q2 results are likely to gain from rising reduced-risk tobacco products demand. However, soft cigarette volumes are a concern.
Zacks Industry Outlook Highlights: Philip Morris International, Altria Group, British American Tobacco, Imperial Tobacco Group and Turning Point Brands
by Zacks Equity Research
Zacks Industry Outlook Highlights: Philip Morris International, Altria Group, British American Tobacco, Imperial Tobacco Group and Turning Point Brands
Tobacco Industry Stock Outlook: Will RRPs Help Heal Burns?
by Zacks Equity Research
Stringent FDA regulations and fading demand for cigarettes plague the performance of most tobacco players. RRPs have been a life saver for a few.
Philip Morris (PM) Q2 Earnings: Will RRPs Steal the Show?
by Zacks Equity Research
Philip Morris' (PM) second-quarter 2018 results are likely to gain from rising RRPs demand. However, cigarette volumes will remain soft.
Meet Juul, the $15 Billion E-Cig Startup with an Identity Crisis
by Nimah Quadri
In a recent fundraising round, e-cigarette maker Juul Labs Inc. raised $650 million, which values the rapidly-growing, yet still-controversial startup around $15 billion.
Philip Morris (PM) Focused on RRPS, Inks Deal with Parallax
by Zacks Equity Research
Phillip Morris (PM) joins hands with Parallax to develop and expand reduced-risk products in order to counter strict government regulations and changing consumer trends due to health hazards.
New Strong Sell Stocks for June 28th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Can RRPS, Pricing Aid Revival at Phillip Morris (PM) Stock?
by Zacks Equity Research
Regulatory hurdles and rising health consciousness have been hurting Phillip Morris (PM) cigarette volumes. However, strength in RRPs and solid pricing efforts bode well.
New Strong Sell Stocks for June 7th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Will Altria (MO) Stock Recover on RRPs and Shareholder Moves?
by Zacks Equity Research
Altria (MO) consistently focuses on strengthening RRPs category to offset declining cigarette volumes. Its shareholder friendly moves bode well.
Is Phillip Morris' Weak Volumes a Concern for Tobacco Firms?
by vidya Nair
Weak shipment volumes stemming from declining cigarette sales have long been a hurdle for firms in the tobacco space. However, RRPs are likely to continue expanding.